Employees: 3,695
Size Shanxi Zhendong Pharmaceutical (300158.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $641M, the 3091st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.43 on 18 Nov 2026.
Performance Over six months the shares fell 22.3%, against -19.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 27.5% over the last twelve months (peer median +0.5%); the operating margin is -25.0% (peer median 9.5%).
Valuation It trades at 1.8× enterprise value to sales against a peer median of 3.0× (5th cheapest of 20).
Capital Return on invested capital runs 18.6 points below its cost of capital (6.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.10B | CN¥2.77B | CN¥2.96B | CN¥3.61B | CN¥3.69B |
| Revenue growth | — | -6% | -18% | -2% | — |
| Gross profit | CN¥1.05B | CN¥1.30B | CN¥1.32B | CN¥1.73B | CN¥1.72B |
| EBITDA | n/a | -CN¥177M | -CN¥517M | CN¥24.7M | CN¥63.4M |
| Net income | -CN¥494M | -CN¥301M | -CN¥1.33B | -CN¥44.0M | -CN¥51.3M |
| Free cash flow | -CN¥304M | -CN¥627M | -CN¥401M | -CN¥306M | CN¥18.3M |
| Capital expenditure | CN¥133M | CN¥179M | CN¥298M | CN¥116M | CN¥146M |
| Total debt | CN¥290M | CN¥231M | CN¥72.7M | CN¥121M | CN¥56.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300158.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.6% | -9.8% | 7th lowest of 21 |
| 6-month return | -22.3% | -19.9% | 9th lowest of 21 |
| Distance from 52-week high | -40.9% | -44.4% | 10th highest of 21 |
| Revenue growth (TTM) | -27.5% | +0.5% | lowest of 20 |
| Operating margin | -25.0% | 9.5% | 2nd lowest of 21 |
| EV / Sales | 1.8× | 3.0× | 5th cheapest of 20 |
| ROIC minus cost of capital | -18.6 pp | +0.4 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | 1.8× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | 1.5× | 4.0% | +13.5% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | 2.0× | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 4.9× | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | 3.4× | 0.4% | +4.8% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 3.8× | 19.1% | +12.1% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | 2.2× | 2.1% | -1.3% |
| ArriVent BioPharma AVBP | United States | $564M | -60% | n/a | -3,620% | 34.2× | n/a | n/a |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $548M | -9% | +6% | 6% | 3.3× | 15.4% | +6.5% |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 1.5× | 14.1% | +15.6% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | n/a | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $532M | -2% | -4% | 21% | 3.0× | 1.4% | +7.0% |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 4.6× | 24.3% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 2.1× | n/a | n/a |
| Lionco Pharmaceutical 603669.SS | China | $474M | +4% | -6% | -17% | 8.4× | n/a | n/a |
| Myung in Pharm 317450.KS | South Korea | $466M | -20% | +7% | 35% | 0.7× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 5.6× | 4.7% | +18.5% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 2.9× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 4.6× | 24.6% | +38.5% |
| Tibet Aim Pharm 002826.SZ | China | $407M | -22% | +13% | 14% | 2.9× | 0.4% | +1.0% |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.01B | -17% | -5% | 4% | 0.9× | 0.5% | +7.9% |